Preclinical evaluation of AMG 925, a FLT3/CDK4 dual kinase inhibitor for treating acute myeloid leukemia

Molecular Cancer Therapeutics

Volumn 13, Issue 4, 2014, Pages 880-889

  Keegan, Kathleen ^a   Li, Cong ^a   Li, Zhihong ^a   Ma, Ji ^a   Ragains, Mark ^a   Coberly, Suzanne ^a   Hollenback, David ^a   Eksterowicz, John ^a   Liang, Lingming ^a   Weidner, Margaret ^a   Huard, Justin ^a   Wang, Xianghong ^a   Alba, Grace ^a   Orf, Jessica ^a   Lo, Mei Chu ^a   Zhao, Sharon ^a   Ngo, Rachel ^a   Chen, Ada ^a   Liu, Lily ^a   Carlson, Timothy ^a   Quéva, Christophe ^a   McGee, Lawrence R ^a   Medina, Julio ^a   Kamb, Alexander ^a   Wickramasinghe, Dineli ^a   Dai, Kang ^a   more..

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [2 [[9 (TRANS 4 METHYLCYCLOHEXYL) 9H PYRIDO[4',3':4,5]PYRROLO[2,3 D]PYRIMIDIN 2YL]7,8DI HYDRO 1,6 NAHPTHYRIDIN 6(5H) 2 OXOETHANOL; AMG 925; ANTINEOPLASTIC AGENT; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; STAT5 PROTEIN; UNCLASSIFIED DRUG; 2-HYDROXY-1-(2-((9-(4-METHYLCYCLOHEXYL)-9H-PYRIDO(4′,3′-4,5)PYRROLO(2,3-D)PYRIMIDIN-2-YL)AMINO)-7,8-DIHYDRO-1,6-NAPHTHYRIDIN-6(5H)-YL)ETHANONE; 6-ACETYL-8-CYCLOPENTYL-5-METHYL-2-(5-PIPERAZIN-1-YLPYRIDIN-2-YLAMINO)-8H-PYRIDO(2,3-D)PYRIMIDIN-7-ONE; CARBANILAMIDE DERIVATIVE; CD135 ANTIGEN; CYCLIN DEPENDENT KINASE 4; FUSED HETEROCYCLIC RINGS; NAPHTHYRIDINE DERIVATIVE; NICOTINAMIDE; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG POTENCY; DRUG SCREENING; DYING; IC 50; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR VOLUME; TUMOR XENOGRAFT; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CELL CYCLE; DOSE RESPONSE; DRUG EFFECTS; EXPERIMENTAL NEOPLASM; GENETICS; HUMAN; LEUKEMIA, MYELOID, ACUTE; NUDE MOUSE; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE; U937 CELL LINE;

ANIMALS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE 4; DOSE-RESPONSE RELATIONSHIP, DRUG; FMS-LIKE TYROSINE KINASE 3; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; LEUKEMIA, MYELOID, ACUTE; MICE; MICE, NUDE; NAPHTHYRIDINES; NEOPLASMS, EXPERIMENTAL; NIACINAMIDE; PHENYLUREA COMPOUNDS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIDINES; SIGNAL TRANSDUCTION; U937 CELLS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84912056282     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-0858     Document Type: Article

References (35)

1. American Cancer Society. Cancer Facts & Figures 2014. Atlanta: American Cancer Society; 2014. http://www.cancer.org.
2. Kayser S, Levis MJ. FLT3 tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitations. Leuk Lymphoma 2014;55:243-55.
3. Smith CC, Wang Q, Chin CS, Salerno S, Damon LE, Levis MJ, et al. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature 2012;485:260-3.
4. Kindler T, Lipka DB, Fischer T. FLT3 as a therapeutic target in AML: still challenging after all these years. Blood 2010;116:5089-102.
5. Grunwald MR, Levis M. FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance. J Int J Hematol 2013;97:683-94.
6. Al-Kali A, Cortes J, Faderl S, Jones D, Abril C, Pierce S, et al. Patterns of molecular response to and relapse after combination of sorafenib, idarubicin, and cytarabine in patients with FLT3 mutant acute myeloid leukemia. Clin Lymphoma Myeloma Leuk 2011;11:361-6.
7. Stone RM, Fischer T, Paquette R, Schiller G, Schiffer CA, Ehninger G, et al. Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia. Leukemia 2012;26:2061-8.
8. Malumbres M, Barbacid M. To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer 2001;1:222-31.
9. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994;264:436-40.
10. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993;366:704-7.
11. Weinberg RA. The retinoblastoma gene and cell growth control. Trends Biochem Sci 1990;15:199-202.
12. Lee WH, Shew JY, Hong FD, Sery TW, Donoso LA, Young LJ, et al. The retinoblastoma susceptibility gene encodes a nuclear phosphoprotein associated with DNA binding activity. Nature 1987;329:642-5.
13. Ortega S, Malumbres M, Barbacid M. Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim Biophys Acta 2002;1602:73-87.
14. Matsuno N, Hoshino K, Nanri T, Kawakita T, Suzushima H, Kawano F, et al. p15 mRNA expression detected by real-time quantitative reverse transcriptase-polymerase chain reaction correlates with the methylation density of the gene in adult acute leukemia. Leuk Res 2005;29:557-64.
15. Drexler HG. Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia- lymphoma cells. Leukemia 1998;12:845-59.
16. Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther 2004;3:1427-38.
17. Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, et al. Results of a randomized phase 2 study of PD 0332991, a cyclindependent kinase (cdk) 4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer. Cancer Res (Supplement) 2012;72:1s-608s (Abstract, 2012 San Antonio Breast Cancer Symposium).
18. Baughn LB, Di Liberto M, Wu K, Toogood PL, Louie T, Gottschalk R, et al. A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6. Cancer Res 2006;66:7661-7.
19. Leonard JP, LaCasce AS, Smith MR, Noy A, Chirieac LR, Rodig SJ, et al. Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. Blood 2012;119:4597-607.
20. Wang L, Wang J, Blaser BW, Duchemin AM, Kusewitt DF, Liu T, et al. Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia. Blood 2007;110:2075-83.
21. Bose P, Simmons GL, Grant S. Cyclin-dependent kinase inhibitor therapy for hematologic malignancies. Expert Opin Investig Drugs 2013;22:723-38.
22. Choudhary C, Brandts C, Schwable J, Tickenbrock L, Sargin B, Ueker A, et al. Activation mechanisms of STAT5 by oncogenic Flt3-ITD. Blood 2007;110:370-4.
23. Malumbres M, Barbacid M. Is cyclin D1-CDK4 kinase a bona fide cancer target? Cancer Cell. 2006;9:2-4.
24. Musgrove EA, Caldon CE, Barraclough J, Stone A, Sutherland RL. Cyclin D as a therapeutic target in cancer. Nat Rev Cancer 2011;11:558-72.
25. Dean JL, Thangavel C, McClendon AK, Reed CA, Knudsen ES. Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure. Oncogene 2010;29:4018-32.
26. Satyanarayana A, Kaldis P. Mammalian cell-cycle regulation: several Cdks, numerous cyclins and diverse compensatory mechanisms. Oncogene 2009;28:2925-39.
27. Lee YM, Sicinski P. Targeting cyclins and cyclin-dependent kinases in cancer: lessons from mice, hopes for therapeutic applications in human. Cell Cycle 2006;5:2110-4.
28. Flaherty KT, Lorusso PM, Demichele A, Abramson VG, Courtney R, Randolph SS, et al. Phase I, dose-escalation trial of the oral cyclindependent kinase 4/6 inhibitor PD 0332991, administered using a 21- day schedule in patients with advanced cancer. Clin Cancer Res 2012;18:568-76.
29. Stone S, Dayananth P, Kamb A. Reversible, p16-mediated cell cycle arrest as protection from chemotherapy. Cancer Res 1996;56:3199-202.
30. McClendon AK, Dean JL, Rivadeneira DB, Yu JE, Reed CA, Gao E, et al. CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy. Cell Cycle. 2012;11:2747-55.
31. von Bubnoff N, Engh RA, Aberg E, Sänger J, Peschel C, Duyster J. FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro. Cancer Res 2009;69:3032-41.
32. Moore AS, Faisal A, Gonzalez de Castro D, Bavetsias V, Sun C, Atrash B, et al. Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns. Leukemia 2012;26:1462-70.
33. Kancha RK, Grundler R, Peschel C, Duyster J. Sensitivity toward sorafenib and sunitinib varies between different activating and drugresistant FLT3-ITD mutations. Exp Hematol 2007;35:1522-6.
34. Farrell P, Shi L, Matuszkiewicz J, Balakrishna D, Hoshino T, Zhang L, et al. Biological characterization of TAK-901, an investigational, novel, multitargeted Aurora B kinase inhibitor. Mol Cancer Ther 2013;12:460-70.
35. Kesarwani M, Huber E, Azam M. Overcoming AC220 resistance of FLT3-ITD by SAR302503. Blood Cancer J. 2013;3:e138.